By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today announced an expanded agreement with healthcare cost management firm MultiPlan to include the MaterniT21 Plus LDT test for fetal aneuploidies.

As a result of the deal, MultiPlan's network of 900,000 providers will have access to Sequenom's test for trisomy 21, 18, and 13. The test was launched in October.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.